Circulatory Biomarkers and Diabetic Retinopathy in Racial and Ethnic Populations

REFERENCES

• Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta. 1968;22(2):296–298. doi:10.1016/0009-8981(68)90372-0.
   PubMed Web of Science ®Google Scholar
• Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136(1):122–135. doi:10.1016/S0002-9394(03)00219-8.
   PubMed Web of Science ®Google Scholar
• Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs—An Extension of the Modified Airlie House Classification: ETDRS Report Number 10. Ophthalmology 1991;98:786–806.
   Google Scholar
• Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Archives of ophthalmology (Chicago, Ill. 1960);103(1985):1796–1806.
   Google Scholar
• Sun JK, Aiello LP, Abràmoff MD, et al. Updating the staging system for diabetic retinal disease. Ophthalmology. 2021;128(4):490–493. doi:10.1016/j.ophtha.2020.10.008.
   PubMed Web of Science ®Google Scholar
• Lammer J, Prager SG, Cheney MC, et al. Cone photoreceptor irregularity on adaptive optics scanning laser ophthalmoscopy correlates with severity of diabetic retinopathy and macular Edema. Invest Ophthalmol Vis Sci. 2016;57(15):6624–6632. doi:10.1167/iovs.16-19537.
   PubMed Web of Science ®Google Scholar
• Silva PS, Cavallerano JD, Haddad NM, et al. Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years. Ophthalmology. 2015;122(5):949–956. doi:10.1016/j.ophtha.2015.01.008.
   PubMed Web of Science ®Google Scholar
• Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O’Neal DN, Januszewski AS. Biomarkers in diabetic retinopathy. Rev Diabet Stud. 2015;12(1–2):159–195. doi:10.1900/RDS.2015.12.159.
   PubMedGoogle Scholar
• Vujosevic S, Simó R. Local and systemic inflammatory biomarkers of diabetic retinopathy: an integrative approach. Invest Ophthalmol Vis Sci. 2017;58(6):BIO68–BIO75. doi:10.1167/iovs.17-21769.
   PubMed Web of Science ®Google Scholar
• Simó-Servat O, Simó R, Hernández C. Circulating biomarkers of diabetic retinopathy: an overview based on physiopathology. J Diabetes Res. 2016;2016:5263798. doi:10.1155/2016/5263798.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–1487. doi:10.1056/NEJM199412013312203.
   PubMed Web of Science ®Google Scholar
• Cagney DN, Sul J, Huang RY, Ligon KL, Wen PY, Alexander BM. The FDA NIH biomarkers, endpoints, and other tools (BEST) resource in neuro-oncology. Neuro Oncol. 2017;20(9):1162–1172. doi:10.1093/neuonc/nox242.
   Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical Research Ed). 2000;321(7258):405–412. doi:10.1136/bmj.321.7258.405.
   PubMed Web of Science ®Google Scholar
• Wieczorek A, Rys P, Skrzekowska-Baran I, Malecki M. The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus. Rev Diabet Stud. 2008;5(3):128–135. doi:10.1900/RDS.2008.5.128.
   PubMedGoogle Scholar
• Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial—revisited. Diabetes (New York, NY). 2008;57:995–1001.
   Google Scholar
• Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab. 2012;97(4):1067–1072. doi:10.1210/jc.2011-1894.
   PubMed Web of Science ®Google Scholar
• Cho H, Sobrin L. Genetics of diabetic retinopathy. Curr Diab Rep. 2014;14(8):515. doi:10.1007/s11892-014-0515-z.
   PubMed Web of Science ®Google Scholar
• Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes. 1997;46(11): 1829–1839.
   PubMed Web of Science ®Google Scholar
• Liu C, Chen G, Bentley AR, et al. Genome-wide association study for proliferative diabetic retinopathy in Africans. NPJ Genom Med. 2019;4(1):20. doi:10.1038/s41525-019-0094-7.
   PubMedGoogle Scholar
• Huang Y-C, Lin J-M, Lin H-J, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology. 2011;118(4):642–648. doi:10.1016/j.ophtha.2010.07.020.
   PubMed Web of Science ®Google Scholar
• Awata T, Yamashita H, Kurihara S, et al. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. PloS one. 2014;9(11):e111715. doi:10.1371/journal.pone.0111715.
   PubMed Web of Science ®Google Scholar
• Sheu W-H-H, Kuo JZ, Lee I-T, et al. Genome-wide association study in a Chinese population with diabetic retinopathy. Hum Mol Genet. 2013;22(15):3165–3173. doi:10.1093/hmg/ddt161.
   PubMed Web of Science ®Google Scholar
• Burdon KP, Fogarty RD, Shen W, et al. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia. 2015;58(10):2288–2297. doi:10.1007/s00125-015-3697-2.
   PubMed Web of Science ®Google Scholar
• Graham PS, Kaidonis G, Abhary S, et al. Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy. BMC Med Genet. 2018;19(1):71. doi:10.1186/s12881-018-0587-8.
   PubMedGoogle Scholar
• Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 2011;20(12):2472–2481. doi:10.1093/hmg/ddr121.
   PubMed Web of Science ®Google Scholar
• Sobrin L, Green T, Sim X, et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci. 2011;52(10):7593–7602. doi:10.1167/iovs.11-7510.
   PubMed Web of Science ®Google Scholar
• Sobrin L, Susarla G, Stanwyck L, et al. Gene set enrichment analsyes identify pathways involved in genetic risk for diabetic retinopathy. Am J Ophthalmol. 2022;233:111–123. doi:10.1016/j.ajo.2021.06.014.
   PubMed Web of Science ®Google Scholar
• Imamura M, Takahashi A, Matsunami M, et al. Genome-wide association studies identify two novel loci conferring susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes. Hum Mol Genet. 2021;30(8):716–726. doi:10.1093/hmg/ddab044.
   PubMed Web of Science ®Google Scholar
• Pollack S, Igo RP Jr., Jensen RA, et al. Multiethnic genome-wide association study of diabetic retinopathy using liability threshold modeling of duration of diabetes and glycemic control. Diabetes. 2019;68(2):441–456. doi:10.2337/db18-0567.
   PubMed Web of Science ®Google Scholar
• Zhu X-R, Yang F-Y, Lu J, et al. Plasma metabolomic profiling of proliferative diabetic retinopathy. Nutr Metab (Lond). 2019;16(1):37. doi:10.1186/s12986-019-0358-3.
   PubMedGoogle Scholar
• Rhee SY, Jung ES, Park HM, et al. Plasma glutamine and glutamic acid are potential biomarkers for predicting diabetic retinopathy. Metabolomics: Official journal of the Metabolomic Society. 2018;14(7):89. doi:10.1007/s11306-018-1383-3.
   PubMed Web of Science ®Google Scholar
• Chen L, Cheng C-Y, Choi H, et al. Plasma metabonomic profiling of diabetic retinopathy. Diabetes. 2016;65(4):1099–1108. doi:10.2337/db15-0661.
   PubMed Web of Science ®Google Scholar
• Sumarriva K, Uppal K, Ma C, et al. Arginine and carnitine metabolites are altered in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2019;60(8):3119–3126. doi:10.1167/iovs.19-27321.
   PubMed Web of Science ®Google Scholar
• Hou X-W, Wang Y, Pan C-W. Metabolomics in diabetic retinopathy: a systematic review. Invest Ophthalmol Vis Sci. 2021;62(10):4.
   PubMed Web of Science ®Google Scholar
• Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14):e93751. doi:10.1172/jci.insight.93751.
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (New York, NY). 1989;246(4935):1306–1309. doi:10.1126/science.2479986.
   Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843–845. doi:10.1038/359843a0.
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–1239. doi:10.1056/NEJMra1005073.
   PubMed Web of Science ®Google Scholar
• Sun JK, Jampol LM. The diabetic retinopathy clinical research network (DRCR.net) and Its contributions to the treatment of diabetic retinopathy. Ophthalmic Res. 2019;62(4):225–230. doi:10.1159/000502779.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ju H, Sun M, Chen H. Serum vascular endothelial growth factor levels correlate with severity of retinopathy in diabetic patients: a systematic review and meta-analysis. Dis Markers. 2019;2019:9401628. doi:10.1155/2019/9401628.
   PubMed Web of Science ®Google Scholar
• Malik RA, Li C, Aziz W, et al. Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. J Cell Mol Med. 2005;9(3):692–697. doi:10.1111/j.1582-4934.2005.tb00499.x.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen S, Jiang F, et al. Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. PloS one. 2014;9(10):e110531. doi:10.1371/journal.pone.0110531.
   PubMed Web of Science ®Google Scholar
• Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol. 2000;17:149–152.
   PubMed Web of Science ®Google Scholar
• Khaliq A, Foreman D, Ahmed A, et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest. 1998;78:109–116.
   PubMed Web of Science ®Google Scholar
• Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353(8):782–792. doi:10.1056/NEJMoa041773.
   PubMed Web of Science ®Google Scholar
• Mesquita J, Castro Sousa JP, Tavares-Ratado P, et al. Comparison of serum and vitreous PIGF in diabetic retinopathy patients and non-diabetic patients. Invest Ophthalmol Vis Sci. 2015;56:5179.
   Web of Science ®Google Scholar
• Davidović S, Babić N, Jovanović S, Barišić S, Grković D, Miljković A. Serum erythropoietin concentration and its correlation with stage of diabetic retinopathy. BMC Ophthalmol. 2019;19(1):227. doi:10.1186/s12886-019-1240-9.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Cancarini A, Morescalchi F, et al. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. Diabetes Metab. 2014;40(6):445–451. doi:10.1016/j.diabet.2014.04.005.
   PubMed Web of Science ®Google Scholar
• Joyal JS, Sitaras N, Binet F, et al. Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood. 2011;117(22):6024–6035. doi:10.1182/blood-2010-10-311589.
   PubMed Web of Science ®Google Scholar
• Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer. 2008;8(8):632–645. doi:10.1038/nrc2404.
   PubMed Web of Science ®Google Scholar
• Kwon SH, Shin JP, Kim IT, Park DH. Association of plasma semaphorin 3A with phenotypes of diabetic retinopathy and nephropathy. Invest Ophthalmol Vis Sci. 2016;57(7):2983–2989. doi:10.1167/iovs.16-19468.
   PubMed Web of Science ®Google Scholar
• Cerani A, Tetreault N, Menard C, et al. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab. 2013;18(4):505–518. doi:10.1016/j.cmet.2013.09.003.
   PubMed Web of Science ®Google Scholar
• Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:095103. doi:10.1155/2007/95103.
   PubMed Web of Science ®Google Scholar
• Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343–358. doi:10.1016/j.preteyeres.2011.05.002.
   PubMed Web of Science ®Google Scholar
• Murugesan N, Ustunkaya T, Feener EP. Thrombosis and hemorrhage in diabetic retinopathy: a perspective from an inflammatory standpoint. Seminars in Thrombosis and Hemostasis. 2015;41(6):659–664.
   PubMed Web of Science ®Google Scholar
• Aveleira CA, Lin C-M, Abcouwer SF, Ambrósio AF, Antonetti DATNF-Α. signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes. 2010;59(11):2872–2882. doi:10.2337/db09-1606.
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. The FASEB Journal. 2002;16(3):438–440. doi:10.1096/fj.01-0707fje.
   PubMed Web of Science ®Google Scholar
• Joussen AM, Doehmen S, Le ML, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis. 2009;15:1418–1428.
   PubMed Web of Science ®Google Scholar
• Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, Graves DT. Diabetes-enhanced tumor necrosis Factor-α production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008;172(5):1411–1418. doi:10.2353/ajpath.2008.071070.
   PubMed Web of Science ®Google Scholar
• Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73–79. doi:10.1016/j.ophtha.2008.09.037.
   PubMed Web of Science ®Google Scholar
• Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20(12):1366–1369. doi:10.1038/sj.eye.6702138.
   PubMed Web of Science ®Google Scholar
• Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. British J Ophthalmol. 1996;80(2):168–173. doi:10.1136/bjo.80.2.168.
   PubMed Web of Science ®Google Scholar
• Kocabora MS, Telli ME, Fazil K, et al. Serum and aqueous concentrations of inflammatory markers in diabetic macular edema. Ocul Immunol Inflamm. 2016;24(5):549–554. doi:10.3109/09273948.2015.1034804.
   PubMed Web of Science ®Google Scholar
• Roy MS, Janal MN, Crosby J, Donnelly R. Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes. Invest Ophthalmol Vis Sci. 2013;54(8):5471–5480. doi:10.1167/iovs.13-12212.
   PubMed Web of Science ®Google Scholar
• Preciado-Puga MC, Malacara JM, Fajardo-Araujo ME, et al. Markers of the progression of complications in patients with type 2 diabetes: a one-year longitudinal study. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association 2014;122:484–490.
   Google Scholar
• Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications. 2008;22(5):309–316. doi:10.1016/j.jdiacomp.2007.03.001.
   PubMed Web of Science ®Google Scholar
• Doganay S, Evereklioglu C, Er H, et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond). 2002;16(2):163–170. doi:10.1038/sj/eye/6700095.
   PubMed Web of Science ®Google Scholar
• Zorena K, Myśliwska J, Myśliwiec M, et al. Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Mediators Inflamm. 2007;2007:092196. doi:10.1155/2007/92196.
   PubMed Web of Science ®Google Scholar
• Klein BEK, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Archives of ophthalmology (Chicago, Ill. 1960;2009(127):1175–1182.
   Google Scholar
• Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales’ disease. Retina (Philadelphia, Pa). 2008;28(6):817–824. doi:10.1097/IAE.0b013e31816576d5.
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110(9):1690–1696. doi:10.1016/S0161-6420(03)00568-2.
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133(1):70–77. doi:10.1016/S0002-9394(01)01269-7.
   PubMed Web of Science ®Google Scholar
• Kocak N, Alacacioglu I, Kaynak S, et al. Comparison of vitreous and plasma levels of vascular endothelial growth factor, interleukin-6 and hepatocyte growth factor in diabetic and non-diabetic retinal detachment cases. Ann Ophthalmol (Skokie). 2010;42:949–956.
   Google Scholar
• Shimizu E, Funatsu H, Yamashita H, Yamashita T, Hori S. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. Jpn J Ophthalmol. 2002;46(1):78–83. doi:10.1016/S0021-5155(01)00452-X.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Alibrahim E, Islam FM, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009;32(9):1704–1709. doi:10.2337/dc09-0102.
   PubMed Web of Science ®Google Scholar
• Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes–the EURODIAB Prospective Complications Study. Diabetologia. 2005;48(2):370–378. doi:10.1007/s00125-004-1628-8.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812. doi:10.1172/JCI200318921.
   PubMed Web of Science ®Google Scholar
• Sanders S, Barnett A, Correa-Velez I, Coulthard M, Doust J. Systematic review of the diagnostic accuracy of C-reactive protein to detect bacterial infection in nonhospitalized infants and children with fever. J Pediatr. 2008;153(4):570–574. doi:10.1016/j.jpeds.2008.04.023.
   PubMed Web of Science ®Google Scholar
• Nowak M, Wielkoszyński T, Marek B, et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med. 2010;10(3):185–192. doi:10.1007/s10238-009-0084-7.
   PubMed Web of Science ®Google Scholar
• Sarangi R, Padhi S, Mohapatra S, et al. Serum high sensitivity C-reactive protein, nitric oxide metabolites, plasma fibrinogen, and lipid parameters in Indian type 2 diabetic males. Diabetes Metab Syndr. 2012;6(1):9–14. doi:10.1016/j.dsx.2012.05.015.
   PubMedGoogle Scholar
• van Hecke MV, Dekker JM, Nijpels G, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn study. Diabetologia. 2005;48(7):1300–1306. doi:10.1007/s00125-005-1799-y.
   PubMed Web of Science ®Google Scholar
• Sasongko MB, Wong TY, Jenkins AJ, Nguyen TT, Shaw JE, Wang JJ. Circulating markers of inflammation and endothelial function, and their relationship to diabetic retinopathy. Diabet Med. 2015;32(5):686–691. doi:10.1111/dme.12640.
   PubMed Web of Science ®Google Scholar
• Spijkerman AM, Gall MA, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabet Med. 2007;24:969–976.
   PubMed Web of Science ®Google Scholar
• Laursen JV, Hoffmann SS, Green A, Nybo M, Sjølie AK, Grauslund J. Associations between diabetic retinopathy and plasma levels of high-sensitive C-reactive protein or von Willebrand factor in long-term type 1 diabetic patients. Curr Eye Res. 2013;38(1):174–179. doi:10.3109/02713683.2012.713153.
   PubMed Web of Science ®Google Scholar
• Lim LS, Tai ES, Mitchell P, et al. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51(9):4458–4463. doi:10.1167/iovs.09-4939.
   PubMed Web of Science ®Google Scholar
• Fickweiler W, Aiello LP, Sun JK, King GL, Fickweiler W, Aiello LP, Sun JK, King GL. Retinol binding protein 3 as biomarker for diabetic retinopathy. Ann Transl Med. 2019;7(22):706. doi:10.21037/atm.2019.10.95.
   PubMed Web of Science ®Google Scholar
• Chan AK, Chiu RW, Lo YM. Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem. 2003;40(2):122–130. doi:10.1258/000456303763046030.
   PubMedGoogle Scholar
• Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Archivio italiano di urologia, andrologia: organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2006;78:125–129.
   Google Scholar
• Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. doi:10.1136/bmj.k3519.
   PubMedGoogle Scholar
• Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268–278. doi:10.1038/nrc2351.
   PubMed Web of Science ®Google Scholar
• Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. Jama. 1995;274(16):1277–1281. doi:10.1001/jama.1995.03530160029029.
   PubMed Web of Science ®Google Scholar
• Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19–48. doi:10.1016/j.preteyeres.2013.02.001.
   PubMed Web of Science ®Google Scholar
• Fickweiler W, Klaassen I, Vogels IMC, et al. Association of circulating markers with outcome parameters in the bevacizumab and ranibizumab in diabetic macular edema trial. Investigative Ophthalmology & Visual Science. 2016;57(14):6234–6241. doi:10.1167/iovs.16-20157.
   PubMed Web of Science ®Google Scholar
• Park PS-H, One C. Constitutively active rhodopsin and retinal disease. In: Tao Y-X, ed. Advances in Pharmacology: Academic Press. 2014:1–36. Oxford, UK: Elsevier Science.
   Google Scholar
• Hamaoui K, Butt A, Powrie J, Swaminathan R. Concentration of Circulating Rhodopsin mRNA in Diabetic Retinopathy. Clin Chem. 2004;50(11):2152–2155. doi:10.1373/clinchem.2004.037168.
   PubMed Web of Science ®Google Scholar
• AN BUTT, SHALCHI Z, HAMAOUI K, et al. Circulating nucleic acids and diabetic complications. Ann N Y Acad Sci. 2006;1075(1):258–270. doi:10.1196/annals.1368.034.
   PubMedGoogle Scholar
• Vijayasarathy C, Ziccardi L, Sieving PA. Biology of retinoschisin. Adv Exp Med Biol. 2012;723:513–518.
   PubMed Web of Science ®Google Scholar
• Molday LL, Hicks D, Sauer CG, Weber BH, Molday RS. Expression of X-linked retinoschisis protein RS1 in photoreceptor and bipolar cells. Invest Ophthalmol Vis Sci. 2001;42:816–825.
   PubMed Web of Science ®Google Scholar
• Molday RS, Kellner U, Weber BHF. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res. 2012;31(3):195–212. doi:10.1016/j.preteyeres.2011.12.002.
   PubMed Web of Science ®Google Scholar
• Shalchi Z, Sandhu HS, Butt AN, Smith S, Powrie J, Swaminathan R. Retina-specific mRNA in the assessment of diabetic retinopathy. Ann N Y Acad Sci. 2008;1137(1):253–257. doi:10.1196/annals.1448.008.
   PubMedGoogle Scholar